Put companies on watchlist
Alzchem Group AG
ISIN: DE000A2YNT30
WKN: A2YNT3
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Alzchem Group AG · ISIN: DE000A2YNT30 · EQS - Company News (96 News)
Country: Germany · Primary market: Germany · EQS NID: 2094409
03 March 2025 05:12PM

Munich is becoming a hotspot for creatine research



EQS-Media / 03.03.2025 / 17:12 CET/CEST

Alzchem Group invites you to the Creatine Conference 2025: Munich is becoming a hotspot for creatine research

The Alzchem Group is once again bringing together the brightest minds in creatine research in 2025 – in the heart of Munich. From March 12 to 15, 2025, the Meliá Hotel will be transformed into a meeting place for scientists, health and nutrition experts, and anyone else interested in learning more about the versatile benefits of creatine.   

The conference will be held in a hybrid format – live on site and online – so that everyone can attend.  

The event is organized by the Creatine for Health Scientific Advisory Board of Alzchem Group AG, the Exercise and Sport Nutrition Laboratory of Texas A&M University and the DBSS Research Division. Together, they provide a high-level platform to highlight the latest findings and innovations in creatine supplementation, from performance enhancement to longevity.    
 

The future starts here
On all four days of the event, participants can look forward to exciting expert presentations on topics such as:   

  • Creatine as a way to combat fatigue symptomes
  • The role of creatine in women’s health 
  • Creatine to support general well-being 
  • How creatine can support cognitive performance 
  • Creatine for a healthy ageing  

The program will be complemented by interactive panel discussions – a perfect opportunity to engage with experts, gain new insights and immerse yourself in the world of creatine research.  
 

Expertise, innovation and networking  
“We at the Alzchem Group are thrilled to be bringing the Creatine Conference 2025 to Munich. This is where the most renowned minds in science, medicine and sports nutrition gather to present groundbreaking discoveries and actively shape the future of health and well-being. This conference is a must for anyone interested in the many uses of creatine – be it for athletic performance, cognitive function or general well-being,” says Martina Spitzer, CSO of the Alzchem Group.   

The organizers warmly invite experts from the fields of medicine, nutrition, sports science and wellness, as well as young researchers, business delegates and students. Of course, all other interested parties are always welcome. Participants can earn credits for continuing education units (CEUs) and continuing medical education (CMEs).  
 

Learn from the best: how to participate
Do you want to be there and benefit from the latest findings? Further information on registration and the detailed program is available here.   

You also have the opportunity to participate in the Creatine Conference 2025 online.   

Find out more and get your ticket now.   

Do you have research to share? Submit your abstract now! Deadline: February 17, 2025   
https://forms.gle/kDfLj2kRkhCTnKdS9  
 

For more information, visit:
www.creatineforhealth.com 
Creatine For Health - YouTube  
 

New book “Creatine – Muscle Metabolism, Fitness, Health & Longevity” explains the many benefits of creatine   
Creatine is much more than just a supplement for athletes: the substance plays a central role in muscle metabolism and offers numerous health benefits. The new book “Creatine – Muscle Metabolism, Fitness, Health & Longevity” by Prof. Dr. Jürgen Giessing and Dr. Robert Percy Marshall provides a well-founded, easy-to-understand presentation of the latest scientific findings on creatine and its many possible applications.  
 

About Alzchem
Alzchem is a globally active specialty chemicals company that is one of the market leaders in most of its fields of activity. Alzchem offers answers to various global developments such as climate change, population growth and increasing life expectancy. We deliver solutions through brands and products of the highest quality and through a sustainable vision to help shape global developments.

The company sees interesting growth prospects for itself in the areas of human and animal nutrition and agriculture in particular. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and creatine products can contribute to a healthy old age as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective.

Alzchem Group AG’s broad product range includes dietary supplements, precursors for PCR tests and pharmaceutical raw materials. These offerings are the company’s response to global trends and developments. Alzchem is ideally positioned in this respect and considers itself well prepared for an environmental future and global developments.

The company employs around 1,730 people at four production sites in Germany and a plant in Sweden, as well as three sales companies in the USA, China and England. Alzchem generated Group sales of EUR 554.2 million and EBITDA of EUR 105.3 million in 2024.

 



End of Media Release


Issuer: Alzchem Group AG
Key word(s): Health

03.03.2025 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Alzchem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone: +498621862888
Fax: +49862186502888
E-mail: ir@alzchem.com
Internet: www.alzchem.com
ISIN: DE000A2YNT30
WKN: A2YNT3
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 2094409

 
End of News EQS Media

2094409  03.03.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2094409&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Alzchem Group AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.